Brexit Deal Rejection Sounds Alarm Bells For Pharma Industry
Executive Summary
The UK parliament’s decision to reject the Brexit deal could make the prospect of a no-deal exit more likely, although further votes today and on March 14 could see lawmakers rule out that option – at least for now – and opt instead for an extension of the Article 50 process. Either way, the certainty sought by industry, in particular the life sciences sector, is as far away as ever.
You may also be interested in...
UK Industry Skeptical Of Govt’s No-Deal Brexit Filing Expectations
The BioIndustry Association’s latest Brexit webinar looked at issues such as companies’ drug filing strategies in a no-deal scenario as well as the costs that industry is likely to incur as a result of changes to regulatory processes.
WHO Launches Twin-Track Procedure To Speed Access To Health Products
A procedure used to accelerate the approval of COVID-19 products during the pandemic is to be applied to all medicines using “synchronized and parallel, but otherwise entirely independent, processes,” the World Health Organization says.
'Don't Compromise The Pharma Innovation System,' Says Outgoing IFPMA Head Thomas Cueni
Thomas Cueni is stepping down after seven years at the helm of the International Federation of Pharmaceutical Manufacturers and Associations. In an interview with the Pink Sheet ahead of his retirement, he reflects on the proposed pandemic treaty, what still needs to be done to ensure equitable access to medicines, the importance of tackling AMR, moves towards regulatory reliance – and what his post-IFPMA life might look like.